Allyx Therapeutics

Treating Neurodegenerative Disease by Selectively Blocking the mGluR5 Receptor

Allyx Therapeutics takes a novel approach to preserve and protect synapses for people living with neurodegenerative diseases. Its lead compound, ALX-001, is a first-in-class oral therapy with a unique mechanism of action at mGluR5. Clinical programs are currently underway in Alzheimer’s disease (Phase 1b) and Parkinson’s Disease (Phase Ib). The company was founded in 2019 by a group of Yale scientists, seasoned biopharma industry executives, and venture capitalists.

Allyx is a Series A stage company and has extensively leveraged both public and private non-dilutive funding sources including funds from the National Institutes of Health (NIH) and the Michael J. Fox Foundation. Elm Street Ventures led the Series A financing. Rob Bettigole is a member of the board of directors.